Aberdeen Group
SAGE

Aberdeen Group’s Sage Therapeutics SAGE Stock Holding History

Aberdeen Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-64,801
Closed -$704K – 962
2024
Q2 		$704K Hold
64,801
– – ﹤0.01% 838
2024
Q1 		$1.21M Hold
64,801
– – ﹤0.01% 818
2023
Q4 		$1.4M Buy
+64,801
New +$1.28M ﹤0.01% 809
2017
Q4 		– Sell
-4,527
Closed -$282K – 795
2017
Q3 		$282K Buy
+4,527
New +$356K ﹤0.01% 772

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Aberdeen Group's SAGE Position: Q3 2024 in Review

Aberdeen Group sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 64,801 shares — an estimated $704K sold.

Aberdeen Group first reported a position in SAGE in Q3 2017 and held it in 4 quarters. The position peaked at $1.4M in Q4 2023. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • Aberdeen Group reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Aberdeen Group sold 64,801 Sage Therapeutics shares in Q3 2024, an estimated $704K.
  • Aberdeen Group first reported a position in Sage Therapeutics in Q3 2017 and held it in 4 quarters.
  • Aberdeen Group's Sage Therapeutics position peaked at $1.4M in Q4 2023.
  • 176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Aberdeen Group's 13F filing for Q3 2024, filed 25 Oct 2024.